Boehringer, Click DTx for schizophrenia clears pivotal trial
Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of digital therapeutic (DTx) CT-155 for schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies. At the European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam this week, the two partners presented data from…